Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Source filing unavailable
Q2 2013 · —
Revenue$1.79B$1.79B−2.0% vs Q2 2012 Net Income$130.00M$130.00MN/M vs Q2 2012 EPS Diluted$0.10$0.10N/M vs Q2 2012 Gross Profit$1,279,000,000+2.3% Operating Income$220,000,000N/M Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
$397,000,000
−2.5%
Free Cash Flowderived$346,000,000−2.5% Margins · derivedGross margin71.4%+3.0 pt vs Q2 2012
Operating margin12.3%+208.5 pt vs Q2 2012
Net margin7.3%+203.0 pt vs Q2 2012